significant increases in contraction amplitudes, non-voiding contractions (NVC), post-void residual, bladder capacity, and compliance compared to sham rats (Fig.1A,B ). Voiding efficiency (VE) was decreased in BOO rats vs. sham rats. mRNA expression levels of A2A and A3 were significantly increased, and A2B levels were significantly decreased in bladder mucosa, but not in detrusor, of BOO rats vs. controls (Fig.1C) . In comparison of A2BKO and WT rats, the NVC number was significantly increased in A2BKO rats compared to WT ( Fig.2A,B) .
INTRODUCTION AND OBJECTIVES:
The Mechanisms leading to detrusor hyperactivity (DH) associated with BPH and the chance of postoperative resolution remains incompletely understood. Identifying urinary markers associated with DH related to BPH, and with the prediction of resolution may further elucidate some of these mechanisms as well as provide prognostic tests. Our objective was to evaluate the expression of EGF, MMP-1, IL-6, NGF and MCP-1 in the urine of patients with BPH undergoing transurethral resection of the prostate (TURP) and identify within these biomarkers which are associated with postoperative outcomes.
METHODS: We analyzed urine samples from 71 patients undergoing TURP from 2011 to 2017. Urinary levels of EGF, MMP-1, IL-6, NGF and MCP-1 (by commercial ELISA kit) normalized to creatinine were analyzed according to prostate volume, IPSS, estimated postvoid residual volume, and urodynamic parameters in the preoperative period and 12 months after surgery.
RESULTS: Urinary levels of MCP-1/Cr were higher in patients presenting DH preoperativerly (1.38 vs 3.6 ng/mL, p[0.002). Regarding persistence of DH 12 months after surgery, the levels of the NGF/Cr (0.13 vs 0.08, p[0.005) and MMP-1/Cr (0.11 vs 0.04, p[0.021) biomarkers were higher among patients in whom DH persisted postoperatively. The biomarker NGF/Cr, with a cutoff of 0.08 had 84% sensitivity and 70% specificity for prediction of persistence of DH (Area under curve 0.77; 95% CI: 0.62-0.92; p[0.006). MMP-1/Cr, with a cutoff of 0.016 had 76% sensitivity and 64% specificity in predicting persistence of DH (AUC 0.72 ; p[0.022) .
CONCLUSIONS: NGF/Cr and MMP-1/Cr were shown to be useful in predicting the persistence of DH in the postoperative period.
INTRODUCTION AND OBJECTIVES: Many elderly men suffer from benign prostatic hyperplasia (BPH) due to aging, but the pathogenesis of BPH remains to be completely elucidated. Recently, chronic ischemia in the prostate has been suggested to be related to BPH. Thus, we evaluated the impact of chronic ischemia on the development of prostatic hyperplasia and the efficacy of phosphodiesterase type 5 (PDE5) inhibitor for hyperplasia in a rat model with chronic ischemia induced by local atherosclerosis.
METHODS: Eighteen male Sprague-Dawley rats weighing 450-500 g were divided into 3 groups: sham operation, regular diet, placebo (SRP group; n [ 6); arterial endothelial injury, high cholesterol diet, placebo (AHP group; n [ 6); or arterial endothelial injury, high cholesterol diet, and tadalafil as a PDE5 inhibitor (AHT group; n [ 6). The endothelial injury in the common iliac arteries was performed using a 2-Fr Fogarty arterial embolectomy catheter through an incision in the femoral artery into the common iliac artery. Diet and oral drugs were administrated for 8 weeks after surgery. At 8 weeks, blood flow to the ventral prostate (VP) was measured using laser speckle blood flow analysis, and the VP was histologically evaluated.
RESULTS: Mean VP weights were 639 AE 43 mg in the AHP group and 460 AE 54 mg in the SRP group, showing a significant enlargement in VP for the AHP group compared with the SRP group (p [ 0.03). Importantly, mean VP weight was 449 AE 62 mg in the AHT group, significantly smaller than that in the AHP group (p [ 0.03) and similar to that in the SRP group. Prostatic blood flow was significantly lower in the AHP group than in the SRP group (p < 0.01). Interestingly, the blood flow was significantly higher in the AHT group than in the AHP group (p [ 0.02). Histologically, mean interstitial area in the prostate of the AHP group was significantly increased compared with that of the SRP group (p < 0.01). Moreover, tadalafil administration attenuated the increase in interstitial area in the prostate (P < 0.01).
CONCLUSIONS: Enlargement of the VP resulted from chronic ischemia induced by local arteriosclerosis. Also, administration of tadalafil attenuated VP enlargement. Chronic ischemia in the prostate might thus contribute to the development of BPH, and PDE5 inhibitors might provide an innovative approach to preventing BPH.
Source of Funding: none

MP06-19 THE COMBINATION TREATMENT WITH SODIUM HYDROSULFIDE AND TADALAFIL RESTORES BLADDER FUNCTION IN A RAT MODEL OF PARTIAL BLADDER OUTLET OBSTRUCTION VIA MODULATION OF HYDROGEN SULFIDE/NITRIC OXIDE PATHWAY
Didem Yilmaz-Oral*, Adana, Turkey; Ecem Kaya-Sezginer, Nur Bayatli, Serap Gur, Ankara, Turkey INTRODUCTION AND OBJECTIVES: Lower urinary tract symptoms (LUTS) in men are strictly linked to benign prostatic hyperplasia (BPH), which may lead to bladder outlet obstruction (BOO). The phosphodiesterase type 5 inhibitor, tadalafil has been approved for the treatment of BPH/LUTS. Hydrogen sulfide (H 2 S), an endogenous gasotransmitter, is generated by cystathionine-b-synthase (CBS), cystathionine-g-lyase (CSE) as well as 3-mercaptopyruvate sulfurtransferase (3-MST) and involved in pathological disorders of the BPH/LUTS. The present study aimed to investigate the possible restorative effect of combined treatment with a H 2 S donor, sodium hydrosulfide (NaHS) and tadalafil on the bladder dysfunction in a rat model of partial BOO (PBOO).
METHODS: Adult Sprague-Dawley rats (n[75) were equally divided into five groups: 1) sham-operated control, 2) PBOO (6-wk), 3) NaHS (6-wk, 5.6 mg/kg/day, i.p.)-PBOO, 4) tadalafil (6-wk, 2 mg/ kg/day, oral)-PBOO and 5) combined treatment with NaHS and tadalafil in PBOO. Rats underwent PBOO surgery by partial ligation of the urethra. The contractile responses of detrusor muscle were obtained from in vitro studies. Bladder tissues were processed for Western blotting, malondialdehyde (MDA) and H 2 S assay.
RESULTS: Combined treatment prevented increased bladder weight as well as decreased contractile responses in the detrusor smooth muscle of PBOO rats. The increased protein expression of neuronal, endothelial and inducible nitric oxide synthase (nNOS, eNOS and iNOS) in obstructed rats was normalized by combination treatment. CSE, CBS and nuclear factor kappa B (NF-kB) protein levels were not significantly different among groups. Surprisingly, decreased 3-MST protein expression was normalized by tadalafil and combined treatment. NaHS or tadalafil monotherapy partially improved increased MDA levels and decreased H 2 S levels in obstructed rats, while combination therapy normalized both MDA and H 2 S levels.
CONCLUSIONS: Significant alterations in the expression of nNOS, eNOS and iNOS as well as MDA and H 2 S levels may contribute to functional impairment in bladder induced by PBOO. We firstly demonstrated that combination therapy improved bladder dysfunction in PBOO rats by modulation of H 2 S/nitric oxide (NO) pathway and oxidative stress. The synergistic effect and crosstalk between H 2 S and NO can control the molecular regulation of bladder function, which supports combined treatment for improving clinical outcomes in men with BPH/LUTS. 
MP06-20 VOIDED VOLUMES PREDICT DEGREE OF PARTIAL BLADDER OUTLET OBSTRUCTION IN A MURINE MODEL
Nicholas Tassone*, Belinda Li, Megan Devine, Robert Dettman, Edward Gong, Chicago, IL INTRODUCTION AND OBJECTIVES: The partial bladder outlet obstruction animal model (pBOO) is commonly used as a model for obstructive uropathy. Unfortunately, pBOO demonstrates variable degrees of obstruction requiring bladder weight (BW) or urodynamic studies to determine true obstruction. Our objective is to identify extent of obstruction by correlating early post-operative Void Stain on Paper (VSOP) assays with ultimate BW in mice.
METHODS: pBOO was performed on 32 mice, and 1-and 4-week VSOPs were quantified for mean voided volume (mVV)
